The CEO of Panion, Anja Holm, presented the progress and the plans for the company’s development at the investor meeting held at Mangold offices in relation with the current share issue. Panion’s epilepsy project has just started the clinical phase with a pilot study...
Panion Animal Health AB develops a novel gene therapy treatment for dogs with epilepsy. The first clinical trial will be conducted at Long Island Veterinary Specialists, Ophthalmology, Surgery, Internal Medicine, Emergency, PLLC (“LIVS”) in New York, USA. It is a...
Panion Animal Health AB invites all interested persons to an investor meeting at Mangolds offices, Engelbrektsplan 2, Stockholm on Friday the 14th of December 2018 from 12 – 13. The occasion for the meeting is to provide information to current and new investors...
Panion Animal Health AB develops a new gene therapy treatment for dogs with epilepsy, based on CombiGene’s vector that is in development for humans. Read the...
Investment Memorandum – The Board of Panion Animal Health AB (publ) publishes the invitation to subscribe for shares in the Company. Subscription period: December 7, 2018 – December 21, 2018 Subscription price: SEK 1 per share. Press release>> Memorandum>> ...
